Abstract

The effectiveness and cost-utility of nasal continuous positive airway pressure (nCPAP) treatment was evaluated in obstructive sleep apnoea syndrome (OSAS), using a 15D health-related quality of life (HRQoL) instrument in a routine clinical setting. In total, 78 OSAS patients (43 receiving nCPAP; 35 receiving lifestyle guidance) were included in the study. nCPAP treatment had a minor effect on the total HRQoL score; only the dimension of sleep improved in both groups. The mean +/- SD number of quality-adjusted life years (QALYs) gained was 0.016 +/- 2.34 in the nCPAP group and 0.386 +/- 1.16 in the lifestyle guidance group. The mean cost per QALY gained was euro73 375 for the nCPAP group and euro845 for the lifestyle guidance group. The effect of nCPAP treatment on the HRQoL in a population of unselected OSAS patients was surprisingly small and the cost per QALY gained was high.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call